

PERCHERON THERAPEUTICS GENERAL MEETING

Melbourne, Australia – 22 April 2025: Percheron Therapeutics Limited (ASX: PER or “the Company”) has been made aware that a letter from the requisitioning shareholder, Powerhouse Ventures Limited, and a pre-filled proxy form have been posted to Percheron shareholders in connection with the upcoming General Meeting of shareholders to be held on 24 April 2025.

This correspondence was not authorised or sent by Percheron Therapeutics, despite containing Percheron’s logo and being designed and formatted in such a way as to appear as correspondence dispatched by the Company.

Whilst the pre-filled proxy forms refer to lodgement of completed forms with the Company’s share registry, **shareholders should note that the reply-paid envelope included with the proxy forms is addressed to the mailbox of an unknown third party who is NOT authorised by the Company to receive or handle proxy forms.**

Proxy forms not received directly by the Company or by the Company’s share registry, Boardroom Pty Ltd, may be declared invalid. Shareholders are reminded that proxy forms must be lodged directly by the member making the appointment at least 48 hours before the appointed time of the General Meeting.

Further information and instructions regarding the completion and lodgement of proxy forms can be found in the Notice of General Meeting lodged with ASX on 14 March 2025.

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTCQB: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company’s lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, which has been investigated in a range of inflammatory conditions, including multiple sclerosis and Duchenne muscular dystrophy. For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.
